Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-18
2006-07-18
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C530S350000, C530S395000
Reexamination Certificate
active
07078375
ABSTRACT:
Provided are protective and deleterious diabetes-mediating proteins and polynucleotides encoding same, transgenic animals expressing a diabetes-mediating protein, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of altering the expression of a diabetes-mediating protein.
REFERENCES:
patent: 5400249 (1995-03-01), Soll et al.
patent: 5424286 (1995-06-01), Eng
patent: 5760001 (1998-06-01), Girten et al.
patent: 5770355 (1998-06-01), Brocia et al.
McLean, M. P. et al. (1995) Differential expression of hepatic sterol carrier proteins in the streptozotocin-treated diabetic rat. Endocrinology. vol. 136, pp. 3360-3368.
Richardson, J. m. (1991) Differential regulation of glucose transporter activity and expression in red and white skeletal muscle. J Biol Chem. vol. 266, pp. 12690-12694.
Ferre T. et al. (1996) Correction of diabetic alterations by glucokinase. Proc Natl Acad Sci U S A. vol. 93, pp. 7225-7230.
Jaffa, A. A. et al. (1992) Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. vol. 41, pp. 789-795.
Ellas, D. et al. (1990) Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A. vol. 87, pp. 1576-1580.
Pugliese, G. et al. (2000) The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes. vol. 49, pp. 1249-1257.
Bluher, M. et al. (2001) Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care. vol. 24, pp. 328-334.
Wachlin, G. et al. (2003) IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destruction. J. Autoimmun. vol. 20, pp. 303-312.
Andersen, H.U. et al., “Genetically determined differences in newborn rat islet sensitivity to interleukin-1 in vitro: no association with the diabetes prone phenotype in the BB-rat,”Acta Endocrinologica(Copenh)120:92-98, Copenhagen, Munksgaard (1989).
Andersen, H.U. et al., “Nicotinamide Prevents Interleukin-1 Effects on Accumulated Insulin Release and Nitric Oxide Production in Rat Islets of Langerhans,”Diabetes 43:770-777, American Diabetes Association (1994).
Andersen, H.U., et al., “Two-Dimensional Gel Electrophoresis of Rat Islet Proteins. Interleukin 1β-Induced Changes in Protein Expression Are Reduced by L-Arginine Depletion and Nicotinamide,”Diabetes 44:400-407, American Diabetes Association (1995).
Appel, R.D. et al., “The MELANIE project: From a Biopsy to Automatic Protein Map Interpretation by Computer,”Electrophoresis 12:722-735, VCH Verlagsgesellschaft mbH (1991).
Christensen, U.B., et al., “Islet Protein Expression at Diabetes Onset in BB-Rats Differs from that Seen During Islet Allograft Rejection,”Diabetologia 38(Suppl 1):A85, Abstract # 327, Springer-Verlag (1995).
Eizirik, D.L. et al., “The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells,”Diabetologia 39:875-890, Springer-Verlag (1996).
Eizirik, D.S. et al., “Role of Receptor Binding and Gene Transcription for Both the Stimulatory and Inhibitory Effects of Interleukin-1 in Pancreatic β-Cells,”Autoimmunity 12:127-133, Harwood Academic Publishers GmbH (1992).
Garrels, J.I. et al., “The QUEST System for Quantitative Analysis of Two-dimensional Gels,”J. Biol. Chem. 264:5269-5282, American Society for Biochemistry and Molecular Biology, Inc (1989).
Giometti, C.S. et al., “Mouse liver protein database: A catalog of proteins detected by two-dimensional gel electrophoresis,”Electrophoresis 13:970-991, VCH Verlagsgesellschaft mbH (1992).
Grunberger, G. et al., “Insulin Receptors in Normal and Disease States,”Clin. Endocrinol. Metab. 12:191-219, W.B. Saunders Company Ltd. (1983).
Helqvist, S. et al., Interleukin 1 induces new protein formation in isolated rat islets of Langerhans,Acta Endocrinologica 121:136-140, Copenhagen, Munksgaard (1989).
Helqvist, S. et al., “Heat shock protein induction in rat pancreatic islets by recombinant human interleukin 1β,”Diabetologia 34:150-156, Springer-Verlag (1991).
Hughes, J.H. et al., “Interleukin 1 Inhibits Insulin Secretion from Isolated Rat Pancreatic Islets by a Process That Requires Gene Transcription and mRNA Translation,”J. Clin. Invest. 86:856-863, The Rockefeller University Press, Inc. (1990).
Jin, J.S. et al., “Shape Representations and Pattern Matching Under the Multi-Channel Theory,”Proceedings of the 3rd Pacific Rim International Conference on Artificial Intelligence, International Academic Publishers, Beijing, China, Aug. 15-18, vol. 2, pp. 970-975 (1994).
Jungblut, P. et al., “Protein analysis on a genomic scale,”J. Biotech. 41:111-120, Elsevier (1995).
Jungblut, P. et al., “Quantitative Analysis of Two-Dimensional Electrophoretic Protein Patterns: Comparison of Visual Evaluation with Computer-Assisted Evaluation,” inElectrophoresis '84(Volker Neuhoff ed.) Göttingen, pp. 301-303, Verlag ChemieGmbH (1984).
Karlsen, A.E. et al., “Cloning and Expression of Cytokine-Inducible Nitric Oxide Synthase cDNA from Rat Islets of Langerhans,”Diabetes 44:753-758, American Diabetes Association (1995).
Karlsen, A.E., et al., “Identification and Characterization of Proteins Involved in Cytokine Mediated β-Cell Destruction and Insulin-Dependent Diabetes Mellitus,”Cytokine 9:912, Abstract # 90, Academic Press (1997).
Knecht, M. et al., “Dilated Cardiomyopathy: Computer-Assisted Analysis of Endomyocardial Biopsy Protein Patterns by 2-D Gel Electrophoresis,”Eur. J. Clin. Chem. Clin. Biochem 32:615-624, Walter de Gruyter & Co. (1994).
Korsgren, O., et al., “Hypergycemia induced B Cell Toxicity. The Fate of Pancreatic Islets Transplanted into Diabetic Mice Is Dependent on Their Genetic Background,”J. Clin. Invest. 86:2161-2168, American Society for Clinical Investigation, Inc. (1990).
Manabe, T. et al., “Studies on the Procedure for the Construction of Cellular Protein Databases Employing micro 2-D Electrophoresis: An HL-60 Protein Database,”Electrophoresis 16:407-422, VCH Verlagsgesellschaft mbH (1995).
Mandrup-Poulsen, T., “The role of interleukin-1 in the pathogenesis of IDDM,”Diabetologia 39:1005-1029, Springer-Verlag (1996).
Mandrup-Poulsen, T., “Islet Cytotoxicity of Interleukin 1: Influence of Culture Conditions and Islet Donor Characteristics,”Diabetes 36:641-647, American Diabetes Association (1987).
Martin, J.-P., “Intelligent imaging automates gel analysis for molecular biology,”Scientific Computing World, pp. 25-28, Cambridge Publishers Ltd. (Sep. 1995).
Microsoft Coproration, Microsoft Excel User's Guide, pp. 305-316 (1992-1993).
O'Farrell, P. H., “High Resolution Two-Dimensional Electrophoresis of Proteins,”J. Biol. Chem. 250:4007-4021, American Society of Biological Chemists, Inc. (1975).
O'Farrell, P.Z. et al., “High Resolution Two-Dimensional Electrophoresis of Basic as Well as Acidic Proteins,”Cell 12:1133-1141, MIT Press (1977).
Pociot, F., et al., “A Comprehensive Approach to Identifying New Susceptibility Genes to Insulin-Dependent Diabetes Mellitus—Combining Proteome and Genome Anayses,”Cytokine 9:899, Abstract #39, Academic Press (1997).
Shi, C.Z. et al., “Protein Databases for Compacted Eight-Cell and Blastocyst-Stage Mouse Embryos,”Mol. Reprod. Develop. 37:34-47, Wiley-Liss, Inc. (1994).
Steiner, S. et al., “Protein variability in male and female Wistar rat liver proteins,”Electrophoresis
Andersen Henrik U.
Christensen Ulla Bjerre
Fey Stephen J.
Karlsen Allan E.
Larsen Peter Mose
Liu Samuel Wei
Weber Jon
LandOfFree
Diabetes-mediating proteins and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diabetes-mediating proteins and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diabetes-mediating proteins and therapeutic uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526423